Overview

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

Status:
Not yet recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

This phase 2 study ain to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy. It will enrolled 46 patients (34 in France and 12 in Australia) through 15 sites (11 in France and 4 in Australia).

Phase:

Phase 2

Details

Lead Sponsor:

Intergroupe Francophone du Myelome

Collaborators:

Celgene
Sanofi

Treatments:

Dexamethasone
Pomalidomide